君實生物(01877.HK)與嘉晨西海設合資從事mRNA技術平台疾病領域的研發及商業化
格隆匯7月19日丨君實生物(01877.HK)公吿,於2021年7月19日,公司與嘉晨西海就成立合資企業(合資企業的中文名稱建議為上海君實西海生物科技有限公司)訂立合資協議。
合資企業的初始註冊資本為人民幣1億元。合資企業將主要從事合資地區從事基於mRNA技術平台的腫瘤、傳染病、罕見疾病及訂約雙方協定的其他疾病領域的研發、臨牀研究、申請批准、生產及產品開發項目商業化。合資企業於成立後將由公司擁有50%及由嘉晨西海擁有50%。
據悉,嘉晨西海是一家專注於自複製和常規mRNA新藥和疫苗開發的創新藥研發公司。2019年成立以來,發展穩健迅速,目前已經建立了一整套適合商業化生產的mRNA合成、純化、分析質控工藝,並研發了表達效力更高的通用mRNA模板(包括自複製和非自複製mRNA)。藉助於其高效的篩選平台,嘉晨西海開發了包括聚合物和納米脂質體顆粒在內的一整套mRNA遞送系統。嘉晨西海擁有多個自主知識產權的分別適用於肌肉、靜脈、組織靶向給藥的陽離子脂複合體。嘉晨西海的管線涵蓋腫瘤免疫治療、傳染病疫苗、罕見病和醫學美容。嘉晨西海的腫瘤免疫和傳染病疫苗項目正快速進入臨牀試驗階段。
公司認為,通過訂立合資協議及成立合資企業,能夠互補雙方各自的技術優勢,更加高效的發揮mRNA通用平台技術在腫瘤、傳染病、罕見病方面的應用潛力,並不斷拓展新的應用方向。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.